6 2020 BAYCREST IMPACT
Whether individuals are seeking to be proactive in attending to their brain health
or have been diagnosed with the early or late stages of a neurodegenerative
disorder, our Rotman Research Institute's new Clinical Trials Unit (CTU) provides
access to experimental treatments that could improve their symptoms.
The CTU was created to respond to a growing need to explore and test new
therapies to prevent and treat dementia. Clinical trials are an essential step in
developing effective treatments for Alzheimer's disease and related dementias.
"There are at least 20 prevention strategies currently available that have the
potential to slow cognitive decline and prevent various forms of dementia," says
Dr. Howard Chertkow, Director of the CTU. "While we still have a long way to go
in having a better understanding of the brain and Alzheimer's disease, there are
promising leads that have been uncovered over the last few decades. Through our
clinical trials, we hope to be able to offer these cutting-edge treatments to clients
and their loved ones, which will also help us gain a better understanding of ways
to further improve treatment development."
Individuals who are 50 years and older may qualify to participate in a Baycrest
clinical trial.
MOVING FORWARD
TREATMENTS FOR DEMENTIA
